Vyant Bio, Inc. - VYNT STOCK NEWS

Vyant Bio (Nasdaq: VYNT), a biotechnology firm specializing in drug discovery for neurodevelopmental and neurodegenerative disorders, announced its participation in the H.C. Wainwright Global Investment Hybrid Conference from May 23-26, 2022. CEO Jay Roberts will present the company's key scientific and business milestones, with slides available in the investor section of their website. Registered attendees can access on-demand presentations starting May 23 at 7:00 am ET. Vyant Bio is focused on innovative drug discovery using human-derived models and machine learning technologies.

Vyant Bio (VYNT) reported significant scientific advancements in drug discovery for neurodevelopmental and neurodegenerative diseases, including a clinical candidate for Rett Syndrome. The company aims to enhance therapeutic options using their innovative drug discovery platforms. Financially, Vyant has initiated a $14.5 million ATM financing and a $15 million equity line of credit, with a cash position of $16.4 million as of March 31, 2022. However, it posted a net loss of $4.8 million from discontinuing operations, primarily due to impairment charges and increased operational costs.

Vyant Bio, a biotechnology company focused on drug discovery for neurodevelopmental and neurodegenerative disorders, announced an investor conference call on May 16, 2022. The call will feature CEO Jay Roberts, CFO Andy LaFrence, and CSO Robert Fremeau, who will provide updates on the company's first-quarter 2022 performance. Vyant Bio leverages human-derived organoid models, machine learning, and advanced screening methods to enhance drug discovery processes, aiming to improve treatment efficacy for conditions like Rett Syndrome and Parkinson’s Disease.

Vyant Bio, Inc. (Nasdaq: VYNT) announced that CEO Jay Roberts will present at BioNJ’s 12th Annual BioPartnering Conference on May 10, 2022, focusing on the company’s drug discovery strategy incorporating quantitative biomarkers. The conference will take place from May 9-13, 2022, with one-on-one meetings available throughout the week. Vyant Bio specializes in therapies for neurodevelopmental and neurodegenerative diseases, utilizing AI and machine learning to enhance drug efficacy predictions. An on-demand replay of the presentation will be available for registered attendees.

Vyant Bio is focusing on drug discovery for neurodevelopmental and neurodegenerative diseases, including Rett Syndrome and familial Parkinson’s Disease. The company is divesting its vivoPharm subsidiary to enhance its drug discovery capabilities. As of December 31, 2021, Vyant Bio reported $20.6 million in cash and an increase in revenue from continuing operations to $1.1 million. However, net losses surged to $40.9 million due to non-cash and merger-related expenses. The company aims to leverage unique biomarkers to improve drug efficacy pre-trial, maximizing shareholder value.

Vyant Bio (Nasdaq: VYNT) and OrganoTherapeutics have partnered to expedite drug discovery for Parkinson's Disease (PD). This collaboration integrates expertise in drug discovery using human-derived cells and machine learning to identify effective drug candidates. By utilizing OrganoTherapeutics' patient-specific organoid models and Vyant's AnalytiX^TM technology, the partnership aims to pinpoint therapeutic approaches targeting genetic mutations in PD. This strategic move reflects Vyant's commitment to innovative therapies for CNS diseases, reinforcing its capabilities in advanced drug development.

Vyant Bio, Inc. (VYNT), a biotechnology company focused on drug discovery for neurodevelopmental and neurodegenerative disorders, announced an investor conference call on March 30, 2022. Key executives will discuss the Year-End 2021 results and provide corporate updates. Vyant Bio's innovative platform combines organoid models, scaled biology, and machine learning, aimed at identifying drug candidates for rare CNS genetic disorders like Rett Syndrome and familial Parkinson's Disease. Investors are encouraged to participate via a webcast available on their website.

Vyant Bio (NADSAQ: VYNT) issued a Letter to Shareholders, highlighting its strategic transformation into a biotechnology firm focused on drug discovery for neurological disorders. The company holds approximately $20 million in cash and aims to initiate clinical trials for novel drug candidates by 2023. Key partnerships and proprietary technologies, like the microBrain platform, are central to its efforts. The 2021 merger with StemoniX and Cancer Genetics is expected to enhance R&D capabilities. However, the firm acknowledges challenges in drug discovery timelines and transitioning to a focused R&D model.

Vyant Bio (Nasdaq: VYNT) is actively participating in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022. This virtual event allows registered attendees to view a recorded presentation on-demand. CEO Jay Roberts and CSO Robert Fremeau, Ph.D., will present key highlights from 2021 and the company's outlook for 2022. Vyant Bio focuses on discovering therapeutics for CNS diseases, leveraging advanced biological and technological methods. The company aims to file two investigational new drug applications annually and will also hold virtual one-on-one meetings for interested investors.